Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Yttrium Y 90 Resin Microspheres Clear all
Recruiting Phase 2 Interventional

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

NCT06860815
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
Interventions
Biopsy, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Transarterial Radioembolization, Yttrium Y 90 Resin Microspheres
Procedure · Biological · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 26, 2026, 2:55 PM EDT
Recruiting Not applicable Interventional

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

NCT03686709
View directory record Official record
Conditions
Hepatocellular Carcinoma, Radiation Exposure
Interventions
Post therapy PET/CT Imaging
Diagnostic Test
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 26, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT01721954
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
FOLFOX6m, SIR-Spheres microspheres
Drug · Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Duarte, California • Orlando, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 26, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases

NCT02416466
View directory record Official record
Conditions
Liver Metastases
Interventions
anti-CEA CAR-T cells, Sir-Spheres
Biological · Device
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional Results available

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT04541173
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Y-90 TARE, Atezolizumab, Bevacizumab
Other · Drug
Lead sponsor
Aiwu Ruth He, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 26, 2026, 2:55 PM EDT
Terminated Not applicable Interventional Results available

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

NCT00503867
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Hepatoma
Interventions
SIR-Spheres microspheres
Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 26, 2026, 2:55 PM EDT
Terminated Not applicable Interventional

Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

NCT00469963
View directory record Official record
Conditions
Liver Cancer
Interventions
quality-of-life assessment, yttrium Y 90 resin microspheres
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 26, 2026, 2:55 PM EDT
Withdrawn Phase 1 Interventional

Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer

NCT02288507
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib, yttrium-90 radioembolization
Drug · Radiation
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 26, 2026, 2:55 PM EDT
Active, not recruiting Not applicable Interventional

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

NCT04736121
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Interventions
Resin microspheres containing yttrium-90 (Y-90)
Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 26, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

NCT00466856
View directory record Official record
Conditions
Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
Interventions
octreotide acetate, yttrium Y 90 resin microspheres
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 26, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy

NCT00972036
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
SIR-spheres® (Selective Internal Radiation Therapy)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 26, 2026, 2:55 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

NCT02807181
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Cisplatin-gemcitabine, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Drug · Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 26, 2026, 2:55 PM EDT
Not listed Phase 2 Interventional

Definitive Therapy for Oligometastatic Solid Malignancies

NCT01898962
View directory record Official record
Conditions
Stage IV or Recurrent Carcinoma or Sarcoma
Interventions
Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose, Subtotal surgical removal plus ablative radiation dose, Radioembolization
Procedure · Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • Boulder, Colorado • Littleton, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 26, 2026, 2:55 PM EDT
Completed Not applicable Interventional Results available

Low-dose Y90 Treatment Planning for HCC

NCT04172714
View directory record Official record
Conditions
HCC, Cancer of Liver, Cancer
Interventions
SIR-Spheres microspheres
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Sep 26, 2026, 2:55 PM EDT
Completed Not applicable Interventional Results available

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT00724503
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
Interventions
SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
Device · Drug
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • North Miami Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

NCT00604409
View directory record Official record
Conditions
Metastatic Liver Cancer
Interventions
SIRT, capecitabine
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 26, 2026, 2:55 PM EDT
Not yet recruiting Not applicable Interventional

End Hole vs. Pressure-Modulated Delivery of Y-90 Resin Microspheres to Liver Metastases.

NCT07791446
View directory record Official record
Conditions
Liver Metastases, Tumor
Interventions
The TriNav Infusion Systems, Standard End Hole Microcatheter
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 26, 2026, 2:55 PM EDT
Completed No phase listed Observational

Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

NCT04903548
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
SIRT with Y-90 resin microspheres
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 26, 2026, 2:55 PM EDT
Terminated Not applicable Interventional

Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma

NCT02512692
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
SIR-Spheres microspheres (Yttrium-90 Microspheres), Gemcitabine, Cisplatin
Device · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 26, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

NCT02602327
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Liver Metastases
Interventions
Tas-102, SIR-Sphere
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 26, 2026, 2:55 PM EDT
Active, not recruiting No phase listed Observational

Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT

NCT02119065
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
positron emission tomography, computed tomography
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 26, 2026, 2:55 PM EDT
Not listed Phase 1Phase 2 Interventional

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

NCT02913417
View directory record Official record
Conditions
Uveal Melanoma, Hepatic Metastases
Interventions
SIR-Spheres® Yttrium 90, ipilimumab, nivolumab
Device · Drug
Lead sponsor
David Minor, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 26, 2026, 2:55 PM EDT
Not listed Phase 2 Interventional

Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery

NCT00436267
View directory record Official record
Conditions
Metastatic Cancer, Pancreatic Cancer
Interventions
fluorouracil, selective external radiation therapy, tomotherapy, yttrium Y 90 glass microspheres, yttrium Y 90 resin microspheres
Drug · Radiation
Lead sponsor
Goshen Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Goshen, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 26, 2026, 2:55 PM EDT
Active, not recruiting Phase 1 Interventional

SIRT With Tremelimumab and Durvalumab for Resectable HCC

NCT05701488
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Durvalumab, Tremelimumab, SIRT
Drug · Device
Lead sponsor
Jiping Wang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 26, 2026, 2:55 PM EDT